Ana M. Ortega‐Villa

Author

Ana M. Ortega‐Villa

National Institute of Allergy and Infectious Diseases ORCID

Also Known As

Ana M Ortega-Villa, Ana M. Ortega-Villa, Ana M. Ortega‐Villa, Ana Maria Ortega-Villa, Ana Maria Ortega‐Villa, Ana Ortega-Villa, Mahoney, Scott

Publications

538

Citations

H-Index

Concepts

All Affiliations

National Institute of Allergy and Infectious Diseases National Institutes of Health Frederick National Laboratory for Cancer Research Institute for Social Security and Services for State Workers Leidos Biomedical Research Inc. (United States)

About

Ana M. Ortega‐Villa is an author at National Institute of Allergy and Infectious Diseases specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	291
2	Immunology	4	4	255
3	Public Health	2	2	125
4	Epidemiology	2	2	127
5	Child Development	1	1	17

Ana M. Ortega‐Villa

Publications

451

Citations

H-Index

Page 1

	Year	Citations
Natural History and Evolution of Anti-Interferon-γ Autoantibody-Associated Immunodeficiency Syndrome in Thailand and the United States Gloria Hong, Ana M. Ortega‐Villa, Sally Hunsberger, Clinical Infectious Diseases ImmunodeficienciesImmunologyUnited StatesHuman RetrovirusAutoinflammatory Disorders	2019	108
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial Tracy J. Ruckwardt, Kaitlyn M. Morabito, Emily Phung, The Lancet Respiratory Medicine VaccinationVaccine SafetyVaccine DevelopmentImmunologyVirology	2021	62
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial Melinda Hamer, Katherine V. Houser, Amelia R. Hofstetter, The Lancet VaccinationVaccine SafetyVaccine DevelopmentVaccine TargetImmunology	2023	62
Characteristics and outcome of facial nerve palsy from Lyme neuroborreliosis in the United States Adriana Marques, Grace M. Okpali, Kelly Liepshutz, Annals of Clinical and Translational Neurology	2022	34
Reappraisal of Idiopathic CD4 Lymphocytopenia at 30 Years Andrea Lisco, Ana M. Ortega‐Villa, Harry Mystakelis, New England Journal of Medicine	2023	32
Severe Mycobacterial Immune Reconstitution Inflammatory Syndrome (IRIS) in Advanced Human Immunodeficiency Virus (HIV) Has Features of Hemophagocytic Lymphohistiocytosis and Requires Prolonged Immune Suppression Joseph M. Rocco, Elizabeth Laidlaw, Frances Galindo, Clinical Infectious Diseases	2022	28
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial Betty Mwesigwa, Katherine V. Houser, Amelia R. Hofstetter, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccine DevelopmentVaccine TargetImmunology	2023	23
Assessment of Osteoporosis and Fracture Risk in Mastocytosis within a North American Cohort Ayelet Makovoz, Jing Wang, Gloria Oshegbo, The Journal of Allergy and Clinical Immunology In Practice Bone DiseaseNorth American CohortBone HealthFracture DiagnosticsFracture Risk	2021	19
Maternal stress and neonatal anthropometry: the NICHD Fetal Growth Studies Deborah A. Wing, Ana M. Ortega‐Villa, William A. Grobman, American Journal of Obstetrics and Gynecology Fetal MedicinePediatricsMaternal StressPregnancyMaternal Health	2017	17
New insights into modeling exposure measurements below the limit of detection Ana M. Ortega‐Villa, Danping Liu, Mary H. Ward, Environmental Epidemiology	2020	15

Page 1